On October 8, Nvidia-backed Firmus concluded its IPO bookbuilding process as investor support showed signs of faltering. Simultaneously, the biotech firm Iambic Therapeutics, also backed by Nvidia, launched its initial public offering in the U.S. market. These developments highlight a mixed reception for Nvidia-affiliated companies seeking public listings on the same day.
The AI-driven biotechnology firm commences its public listing process to capitalize on investor interest in AI-integrated healthcare solutions.
Read the full storyFirmus concluded its $5 billion IPO bookbuilding process following reports that investor interest weakened during the final stages of the offering.
